{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T01:04:05Z","timestamp":1788311045207,"version":"build-2803163510"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2014,3,6]],"date-time":"2014-03-06T00:00:00Z","timestamp":1394064000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Naunyn-Schmiedeberg's Arch Pharmacol"],"published-print":{"date-parts":[[2014,6]]},"DOI":"10.1007\/s00210-014-0966-4","type":"journal-article","created":{"date-parts":[[2014,3,5]],"date-time":"2014-03-05T03:56:38Z","timestamp":1393991798000},"page":"545-557","source":"Crossref","is-referenced-by-count":31,"title":["Antipsychotic, antidepressant, and cognitive-impairment properties of antipsychotics: rat profile and implications for behavioral and psychological symptoms of dementia"],"prefix":"10.1007","volume":"387","author":[{"given":"Marcin","family":"Ko\u0142aczkowski","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pawe\u0142","family":"Mierzejewski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Przemyslaw","family":"Bienkowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Weso\u0142owska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrian","family":"Newman-Tancredi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2014,3,6]]},"reference":[{"key":"966_CR1","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1016\/S0022-3565(24)35047-5","volume":"290","author":"P Andin\u00e9","year":"1999","unstructured":"Andin\u00e9 P, Widermark N, Axelsson R et al (1999) Characterization of MK-801-induced behavior as a putative rat model of psychosis. J Pharmacol Exp Ther 290:1393\u20131408","journal-title":"J Pharmacol Exp Ther"},{"key":"966_CR2","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/B978-0-12-385902-0.00006-1","volume":"96","author":"J Arnt","year":"2011","unstructured":"Arnt J, Olsen CK (2011) 5-HT6 receptor ligands and their antipsychotic potential. Int Rev Neurobiol 96:141\u2013161. doi: 10.1016\/B978-0-12-385902-0.00006-1","journal-title":"Int Rev Neurobiol"},{"key":"966_CR3","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1358\/dof.2008.033.09.1236966","volume":"33","author":"J Arnt","year":"2008","unstructured":"Arnt J, Bang-Andersen B, Dias R, B\u00f8ges\u00f8 KP (2008) Strategies for pharmacotherapy of schizophrenia. Drugs Future 33:777\u2013791","journal-title":"Drugs Future"},{"key":"966_CR4","doi-asserted-by":"crossref","unstructured":"Ballard C, Waite J (2006) The effectiveness of atypical antipsychotics for the treatment of aggression and psychosis in Alzheimer\u2019s disease. Cochrane Database Syst Rev CD003476. doi: 10.1002\/14651858.CD003476.pub2","DOI":"10.1002\/14651858.CD003476.pub2"},{"key":"966_CR5","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1097\/YCO.0b013e32833111f9","volume":"22","author":"C Ballard","year":"2009","unstructured":"Ballard C, Corbett A, Chitramohan R, Aarsland D (2009) Management of agitation and aggression associated with Alzheimer\u2019s disease: controversies and possible solutions. Curr Opin Psychiatr 22:532\u2013540. doi: 10.1097\/YCO.0b013e32833111f9","journal-title":"Curr Opin Psychiatr"},{"key":"966_CR6","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1097\/FBP.0b013e3280ae6c96","volume":"18","author":"L Bardin","year":"2007","unstructured":"Bardin L, Auclair A, Kleven MS et al (2007) Pharmacological profiles in rats of novel antipsychotics with combined dopamine D2\/serotonin 5-HT1A activity: comparison with typical and atypical conventional antipsychotics. Behav Pharmacol 18:103\u2013118. doi: 10.1097\/FBP.0b013e3280ae6c96","journal-title":"Behav Pharmacol"},{"key":"966_CR7","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1007\/s00213-010-1798-7","volume":"213","author":"GV Carr","year":"2011","unstructured":"Carr GV, Schechter LE, Lucki I (2011) Antidepressant and anxiolytic effects of selective 5-HT6 receptor agonists in rats. Psychopharmacology (Berl) 213:499\u2013507. doi: 10.1007\/s00213-010-1798-7","journal-title":"Psychopharmacology (Berl)"},{"key":"966_CR8","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/j.pnpbp.2012.04.018","volume":"38","author":"BA Chindo","year":"2012","unstructured":"Chindo BA, Adzu B, Yahaya TA, Gamaniel KS (2012) Ketamine-enhanced immobility in forced swim test: a possible animal model for the negative symptoms of schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 38:310\u2013316. doi: 10.1016\/j.pnpbp.2012.04.018","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"966_CR9","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1097\/01.jcp.0000178415.22309.8f","volume":"25","author":"P Deyn De","year":"2005","unstructured":"De Deyn P, Jeste DV, Swanink R et al (2005) Aripiprazole for the treatment of psychosis in patients with Alzheimer\u2019s disease: a randomized, placebo-controlled study. J Clin Psychopharmacol 25:463\u2013467","journal-title":"J Clin Psychopharmacol"},{"key":"966_CR10","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.bbr.2007.08.012","volume":"186","author":"T Enomoto","year":"2008","unstructured":"Enomoto T, Ishibashi T, Tokuda K et al (2008) Lurasidone reverses MK-801-induced impairment of learning and memory in the Morris water maze and radial-arm maze tests in rats. Behav Brain Res 186:197\u2013207. doi: 10.1016\/j.bbr.2007.08.012","journal-title":"Behav Brain Res"},{"key":"966_CR11","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1007\/s10072-012-1126-6","volume":"33","author":"A Fasano","year":"2012","unstructured":"Fasano A, Plotnik M, Bove F, Berardelli A (2012) The neurobiology of falls. Neurol Sci 33:1215\u20131223. doi: 10.1007\/s10072-012-1126-6","journal-title":"Neurol Sci"},{"key":"966_CR12","doi-asserted-by":"crossref","first-page":"2112","DOI":"10.1016\/S0140-6736(05)67889-0","volume":"366","author":"CP Ferri","year":"2005","unstructured":"Ferri CP, Prince M, Brayne C et al (2005) Global prevalence of dementia: a Delphi consensus study. Lancet 366:2112\u20132117. doi: 10.1016\/S0140-6736(05)67889-0","journal-title":"Lancet"},{"key":"966_CR13","doi-asserted-by":"crossref","unstructured":"Gareri P, De Fazio P, Manfredi VG, De Sarro G (2014) Use and safety of antipsychotics in behavioral disorders in elderly people with dementia. J Clin Psychopharmacol 34:109\u2013123","DOI":"10.1097\/JCP.0b013e3182a6096e"},{"key":"966_CR14","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1007\/BF03401577","volume":"1","author":"CE Glatt","year":"1995","unstructured":"Glatt CE, Snowman AM, Sibley DR, Snyder SH (1995) Clozapine: selective labeling of sites resembling 5HT6 serotonin receptors may reflect psychoactive profile. Mol Med 1:398\u2013406","journal-title":"Mol Med"},{"key":"966_CR15","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1097\/FBP.0b013e328343d804","volume":"22","author":"A Gravius","year":"2011","unstructured":"Gravius A, Laszy J, Pietraszek M et al (2011) Effects of 5-HT6 antagonists, Ro-4368554 and SB-258585, in tests used for the detection of cognitive enhancement and antipsychotic-like activity. Behav Pharmacol 22:122\u2013135. doi: 10.1097\/FBP.0b013e328343d804","journal-title":"Behav Pharmacol"},{"key":"966_CR16","unstructured":"H. Lundbeck A\/S (2012) Lundbeck\u2019s Lu AE58054 meets primary endpoint in large placebo-controlled clinical proof of concept study in people with Alzheimer\u2019s disease. Corporate release 472:1\u20134. Available from: http:\/\/investor.lundbeck.com\/releasedetail.cfm?ReleaseID=677436 . Accessed 23 Oct 2012"},{"key":"966_CR17","doi-asserted-by":"crossref","first-page":"611","DOI":"10.2147\/CIA.S1698","volume":"2","author":"EC Hersch","year":"2007","unstructured":"Hersch EC, Falzgraf S (2007) Management of the behavioral and psychological symptoms of dementia. Clin Interv Aging 2:611\u2013621","journal-title":"Clin Interv Aging"},{"key":"966_CR18","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1007\/s00213-011-2561-4","volume":"221","author":"M Horiguchi","year":"2012","unstructured":"Horiguchi M, Meltzer HY (2012) The role of 5-HT1A receptors in phencyclidine (PCP)-induced novel object recognition (NOR) deficit in rats. Psychopharmacology (Berl) 221:205\u2013215. doi: 10.1007\/s00213-011-2561-4","journal-title":"Psychopharmacology (Berl)"},{"key":"966_CR19","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1124\/jpet.111.180638","volume":"338","author":"M Horiguchi","year":"2011","unstructured":"Horiguchi M, Huang M, Meltzer HY (2011) The role of 5-hydroxytryptamine 7 receptors in the phencyclidine-induced novel object recognition deficit in rats. J Pharmacol Exp Ther 338:605\u2013614. doi: 10.1124\/jpet.111.180638","journal-title":"J Pharmacol Exp Ther"},{"key":"966_CR20","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1124\/jpet.110.167346","volume":"334","author":"T Ishibashi","year":"2010","unstructured":"Ishibashi T, Horisawa T, Tokuda K et al (2010) Pharmacological profile of lurasidone, a novel antipsychotic agent with potent 5-hydroxytryptamine 7 (5-HT7) and 5-HT1A receptor activity. J Pharmacol Exp Ther 334:171\u2013181. doi: 10.1124\/jpet.110.167346","journal-title":"J Pharmacol Exp Ther"},{"key":"966_CR21","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.ejphar.2007.06.058","volume":"572","author":"T Ishiyama","year":"2007","unstructured":"Ishiyama T, Tokuda K, Ishibashi T et al (2007) Lurasidone (SM-13496), a novel atypical antipsychotic drug, reverses MK-801-induced impairment of learning and memory in the rat passive-avoidance test. Eur J Pharmacol 572:160\u2013170. doi: 10.1016\/j.ejphar.2007.06.058","journal-title":"Eur J Pharmacol"},{"key":"966_CR22","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1038\/sj.npp.1301492","volume":"33","author":"DV Jeste","year":"2008","unstructured":"Jeste DV, Blazer D, Casey D et al (2008) ACNP White Paper: update on use of antipsychotic drugs in elderly persons with dementia. Neuropsychopharmacology 33:957\u2013970. doi: 10.1038\/sj.npp.1301492","journal-title":"Neuropsychopharmacology"},{"issue":"3","key":"966_CR23","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.pbb.2007.12.015","volume":"89","author":"Y Kitamura","year":"2008","unstructured":"Kitamura Y, Akiyama K, Kitagawa K, Shibata K, Kawasaki H, Suemaru K, Araki H, Sendo T, Gomita Y (2008) Chronic coadministration of carbamazepine together with imipramine produces antidepressant-like effects in an ACTH-induced animal model of treatment-resistant depression: involvement of 5-HT2A receptors? Pharmacol Biochem Behav 89(3):235\u2013240","journal-title":"Pharmacol Biochem Behav"},{"key":"966_CR24","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/S0022-3565(24)37788-2","volume":"287","author":"W Koek","year":"1998","unstructured":"Koek W, Patoiseau JF, Assi\u00e9 MB et al (1998) F 11440, a potent, selective, high efficacy 5-HT1A receptor agonist with marked anxiolytic and antidepressant potential. J Pharmacol Exp Ther 287:266\u2013283","journal-title":"J Pharmacol Exp Ther"},{"key":"966_CR25","doi-asserted-by":"crossref","unstructured":"Ko\u0142aczkowski M, Mierzejewski P, Bie\u0144kowski P, Weso\u0142owska A, Newman-Tancredi A (2013) ADN-1184 a monoaminergic ligand with 5-HT6\/7 receptor antagonism: pharmacological profile and potential therapeutic utility. Br J Pharmacol. doi: 10.1111\/bph.12509","DOI":"10.1111\/bph.12509"},{"key":"966_CR26","doi-asserted-by":"crossref","unstructured":"Komossa K, Depping AM, Gaudchau A, et al. (2010) Second-generation antipsychotics for major depressive disorder and dysthymia. Cochrane Database Syst Rev CD008121. doi: 10.1002\/14651858.CD008121.pub2","DOI":"10.1002\/14651858.CD008121.pub2"},{"key":"966_CR27","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.ejphar.2007.09.016","volume":"578","author":"JV Leite","year":"2008","unstructured":"Leite JV, Guimar\u00e3es FS, Moreira FA (2008) Aripiprazole, an atypical antipsychotic, prevents the motor hyperactivity induced by psychotomimetics and psychostimulants in mice. Eur J Pharmacol 578:222\u2013227. doi: 10.1016\/j.ejphar.2007.09.016","journal-title":"Eur J Pharmacol"},{"issue":"8","key":"966_CR28","doi-asserted-by":"crossref","first-page":"818","DOI":"10.2174\/156720511798192736","volume":"8","author":"CU Lithner","year":"2011","unstructured":"Lithner CU, Hedberg MM, Nordberg A (2011) Transgenic mice as a model for Alzheimer\u2019s disease. Curr Alzheimer Res 8(8):818\u2013831, Review","journal-title":"Curr Alzheimer Res"},{"key":"966_CR29","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1046\/j.1471-4159.2000.740693.x","volume":"74","author":"G Lucas","year":"2000","unstructured":"Lucas G, Spampinato U (2000) Role of striatal serotonin2A and serotonin2C receptor subtypes in the control of in vivo dopamine outflow in the rat striatum. J Neurochem 74:693\u2013701","journal-title":"J Neurochem"},{"key":"966_CR30","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1007\/s00213-009-1570-z","volume":"206","author":"HM Marston","year":"2009","unstructured":"Marston HM, Young JW, Martin FDC et al (2009) Asenapine effects in animal models of psychosis and cognitive function. Psychopharmacology (Berl) 206:699\u2013714. doi: 10.1007\/s00213-009-1570-z","journal-title":"Psychopharmacology (Berl)"},{"key":"966_CR31","doi-asserted-by":"crossref","first-page":"134","DOI":"10.3371\/CSRP.6.3.5","volume":"6","author":"HY Meltzer","year":"2012","unstructured":"Meltzer HY (2012) Clozapine. Clin Schizophr Relat Psychoses 6:134\u2013144. doi: 10.3371\/CSRP.6.3.5","journal-title":"Clin Schizophr Relat Psychoses"},{"issue":"2\u20133","key":"966_CR32","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/S0165-0173(02)00268-0","volume":"41","author":"T Myhrer","year":"2003","unstructured":"Myhrer T (2003) Neurotransmitter systems involved in learning and memory in the rat: a meta-analysis based on studies of four behavioral tasks. Brain Res Brain Res Rev 41(2\u20133):268\u2013287","journal-title":"Brain Res Brain Res Rev"},{"key":"966_CR33","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1007\/s00213-011-2247-y","volume":"216","author":"A Newman-Tancredi","year":"2011","unstructured":"Newman-Tancredi A, Kleven MS (2011) Comparative pharmacology of antipsychotics possessing combined dopamine D2 and serotonin 5-HT1A receptor properties. Psychopharmacology (Berl) 216:451\u2013473. doi: 10.1007\/s00213-011-2247-y","journal-title":"Psychopharmacology (Berl)"},{"key":"966_CR34","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.neuropharm.2007.10.010","volume":"54","author":"RE Nordquist","year":"2008","unstructured":"Nordquist RE, Risterucci C, Moreau JL et al (2008) Effects of aripiprazole\/OPC-14597 on motor activity, pharmacological models of psychosis, and brain activity in rats. Neuropharmacology 54:405\u2013416. doi: 10.1016\/j.neuropharm.2007.10.010","journal-title":"Neuropharmacology"},{"key":"966_CR35","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1007\/BF00179179","volume":"90","author":"SO Ogren","year":"1986","unstructured":"Ogren SO, Hall H, K\u00f6hler C et al (1986) The selective dopamine D2 receptor antagonist raclopride discriminates between dopamine-mediated motor functions. Psychopharmacology (Berl) 90:287\u2013294","journal-title":"Psychopharmacology (Berl)"},{"key":"966_CR36","doi-asserted-by":"crossref","first-page":"746","DOI":"10.2174\/156720512801322564","volume":"9","author":"D Olivares","year":"2012","unstructured":"Olivares D, Deshpande VK, Shi Y et al (2012) N-Methyl D-aspartate (NMDA) receptor antagonists and memantine treatment for Alzheimer\u2019s disease, vascular dementia and Parkinson\u2019s disease. Curr Alzheimer Res 9:746\u2013758","journal-title":"Curr Alzheimer Res"},{"key":"966_CR37","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/0014-2999(78)90118-8","volume":"47","author":"RD Porsolt","year":"1978","unstructured":"Porsolt RD, Anton G, Blavet N, Jalfre M (1978) Behavioural despair in rats: a new model sensitive to antidepressant treatments. Eur J Pharmacol 47:379\u2013391","journal-title":"Eur J Pharmacol"},{"key":"966_CR38","doi-asserted-by":"crossref","first-page":"213","DOI":"10.2165\/00023210-199809030-00005","volume":"9","author":"MN Potenza","year":"1998","unstructured":"Potenza MN, McDougle CJ (1998) Potential of atypical antipsychotics in the treatment of nonpsychotic disorders. CNS Drugs 9:213\u2013232","journal-title":"CNS Drugs"},{"key":"966_CR39","doi-asserted-by":"crossref","first-page":"2657","DOI":"10.1038\/sj.npp.1301654","volume":"33","author":"JS Rodefer","year":"2008","unstructured":"Rodefer JS, Nguyen TN, Karlsson J-J, Arnt J (2008) Reversal of subchronic PCP-induced deficits in attentional set shifting in rats by sertindole and a 5-HT6 receptor antagonist: comparison among antipsychotics. Neuropsychopharmacology 33:2657\u20132666. doi: 10.1038\/sj.npp.1301654","journal-title":"Neuropsychopharmacology"},{"key":"966_CR40","doi-asserted-by":"crossref","DOI":"10.1176\/appi.books.9781585623860","volume-title":"Textbook of psychopharmacology","author":"AF Schatzberg","year":"2009","unstructured":"Schatzberg AF, Nemeroff CB (2009) Textbook of psychopharmacology, 4th edn. American Psychiatric, Washington, DC","edition":"4"},{"key":"966_CR41","first-page":"210","volume":"7","author":"K Scheuer","year":"1996","unstructured":"Scheuer K, Maras A, Gattaz WF et al (1996) Cortical NMDA receptor properties and membrane fluidity are altered in Alzheimer\u2019s disease. Dementia 7:210\u2013214","journal-title":"Dementia"},{"issue":"3","key":"966_CR42","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1097\/01.JGP.0000200589.01396.6d","volume":"14","author":"LS Schneider","year":"2006","unstructured":"Schneider LS, Dagerman K, Insel PS (2006a) Efficacy and adverse effects of atypical antipsychotics for dementia: meta-analysis of randomized, placebo-controlled trials. Am J Geriatr Psychiatry 14(3):191\u2013210","journal-title":"Am J Geriatr Psychiatry"},{"issue":"15","key":"966_CR43","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1056\/NEJMoa061240","volume":"355","author":"LS Schneider","year":"2006","unstructured":"Schneider LS, Tariot PN, Dagerman KS, Davis SM, Hsiao JK, Ismail MS, Lebowitz BD, Lyketsos CG, Ryan JM, Stroup TS, Sultzer DL, Weintraub D, Lieberman JA, CATIE-AD Study Group (2006b) Effectiveness of atypical antipsychotic drugs in patients with Alzheimer\u2019s disease. N Engl J Med 355(15):1525\u20131538","journal-title":"N Engl J Med"},{"key":"966_CR44","doi-asserted-by":"crossref","unstructured":"Schulze J, Glaeske G, van den Bussche H, Kaduszkiewicz H, Koller D, Wiese B, Hoffmann F (2013a) Prescribing of antipsychotic drugs in patients with dementia: a comparison with age-matched and sex-matched non-demented controls. Pharmacoepidemiol Drug Saf. doi: 10.1002\/pds.3527","DOI":"10.1002\/pds.3527"},{"key":"966_CR45","doi-asserted-by":"crossref","unstructured":"Schulze J, van den Bussche H, Glaeske G, Kaduszkiewicz H, Wiese B, Hoffmann F (2013b) Impact of safety warnings on antipsychotic prescriptions in dementia: nothing has changed but the years and the substances. Eur Neuropsychopharmacol 23(9):1034\u20131042. doi: 10.1016\/j.euroneuro.2013.02.001","DOI":"10.1016\/j.euroneuro.2013.02.001"},{"key":"966_CR46","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1001\/jama.293.5.596","volume":"293","author":"KM Sink","year":"2005","unstructured":"Sink KM, Holden KF, Yaffe K (2005) Pharmacological treatment of neuropsychiatric symptoms of dementia: a review of the evidence. JAMA 293:596\u2013608. doi: 10.1001\/jama.293.5.596","journal-title":"JAMA"},{"key":"966_CR47","doi-asserted-by":"crossref","first-page":"141","DOI":"10.2174\/1568007024606195","volume":"1","author":"CA Tamminga","year":"2002","unstructured":"Tamminga CA, Carlsson A (2002) Partial dopamine agonists and dopaminergic stabilizers, in the treatment of psychosis. Curr Drug Targets CNS Neurol Disord 1:141\u2013147","journal-title":"Curr Drug Targets CNS Neurol Disord"},{"key":"966_CR48","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1097\/YIC.0b013e32834d6f91","volume":"27","author":"RH Weisler","year":"2012","unstructured":"Weisler RH, Montgomery SA, Earley WR et al (2012) Efficacy of extended release quetiapine fumarate monotherapy in patients with major depressive disorder: a pooled analysis of two 6-week, double-blind, placebo-controlled studies. Int Clin Psychopharmacol 27:27\u201339. doi: 10.1097\/YIC.0b013e32834d6f91","journal-title":"Int Clin Psychopharmacol"},{"key":"966_CR49","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1097\/FBP.0b013e3283423d6b","volume":"22","author":"A Wesolowska","year":"2011","unstructured":"Wesolowska A, Partyka A, Jastrzebska-Wiesek M et al (2011) Tail suspension test does not detect antidepressant-like properties of atypical antipsychotics. Behav Pharmacol 22:7\u201313","journal-title":"Behav Pharmacol"},{"key":"966_CR50","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1124\/mol.111.076141","volume":"81","author":"EY Yuen","year":"2012","unstructured":"Yuen EY, Li X, Wei J et al (2012) The novel antipsychotic drug lurasidone enhances N-methyl-D-aspartate receptor-mediated synaptic responses. Mol Pharmacol 81:113\u2013119. doi: 10.1124\/mol.111.076141","journal-title":"Mol Pharmacol"}],"container-title":["Naunyn-Schmiedeberg's Archives of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00210-014-0966-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-014-0966-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-014-0966-4","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,2]],"date-time":"2025-05-02T00:08:42Z","timestamp":1746144522000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00210-014-0966-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,3,6]]},"references-count":50,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2014,6]]}},"alternative-id":["966"],"URL":"https:\/\/doi.org\/10.1007\/s00210-014-0966-4","relation":{},"ISSN":["0028-1298","1432-1912"],"issn-type":[{"value":"0028-1298","type":"print"},{"value":"1432-1912","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,3,6]]}}}